

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2025 P 2210-6
Program	Prior Authorization/Medical Necessity
Medication	Ruconest® (C1 esterase inhibitor [recombinant])
P&T Approval Date	6/2020, 4/2021, 4/2022, 4/2023, 4/2024, 4/2025
Effective Date	7/1/2025

1. Background:

Ruconest (C1 esterase inhibitor [recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

Effectiveness was not established in HAE patients with laryngeal attacks.

2. Coverage Criteria ^a:

A. Initial Authorization

1. **Ruconest** will be approved based on **all** of the following criteria:

a. Diagnosis of hereditary angioedema (HAE) as confirmed by **one** of the following:

(1) C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as documented by **one** of the following (per laboratory standard):

- (a) C1-INH antigenic level below the lower limit of normal
- (b) C1-INH functional level below the lower limit of normal

-OR-

(2) HAE with normal C1 inhibitor levels and **one** of the following:

- (a) Confirmed presence of variant(s) in the gene(s) for factor XII, angiotensin-converting enzyme 1, plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosaminase 3-O-sulfotransferase 6
- (b) Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema
- (c) Recurring angioedema attacks that are refractory to high-dose antihistamines with unknown background de-novo mutation(s) (i.e., no family history) (HAE-unknown)

-AND-

b. **Both** of the following:

(1) Prescribed for the acute treatment of HAE attacks

-AND-

- (2) Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Firazyr)

-AND-

- c. Prescribed by **one** of the following:

- (1) Immunologist
(2) Allergist

Authorization of therapy will be issued for 12 months.

B. Reauthorization

1. **Ruconest** will be approved based on **all** of the following criteria:

- a. Documentation of positive clinical response to Ruconest therapy

-AND-

- b. **Both** of the following:

- (1) Prescribed for the acute treatment of HAE attacks

-AND-

- (2) Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Firazyr)

-AND-

- c. Prescribed by **one** of the following:

- (1) Immunologist
(2) Allergist

Authorization of therapy will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Programs:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:

1. Ruconest [package insert]. Warren, NJ: Pharming Healthcare, Inc.; April 2020.
2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. *Allergy*. 2018 Jan 10.
3. Wu, E. Hereditary angioedema with normal C1 inhibitor. In: UpToDate, Saini, S (Ed), UpToDate, Waltham, MA, 2024.
4. Busse, P., Christiansen, S., Riedl, M., et. al. "US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema." *The Journal of Allergy and Clinical Immunology*. 2020 September 05.
5. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. *Allergy*. 2022;77(7):1961-1990. doi:10.1111/all.15214

Program	Prior Authorization/Medical Necessity - Ruconest (C1 esterase inhibitor [recombinant])
Change Control	
6/2020	New program.
4/2021	Added diagnosis criteria. Updated references.
4/2022	Updated references.
4/2023	Annual review. Updated references.
4/2024	Annual review with update to examples of genetic variant(s) and diagnostic criteria with normal C1 inhibitor levels. Updated language for reauthorization criteria.
4/2025	Annual review. No changes to coverage criteria.